

- Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, et al. Vascular permeability factor mRNA and protein expression in human kidney. *Kidney Int* 1992;42:1457–61.
- Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. *Ann Neurol* 2005;57:373–80.
- Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. *Behav Res Meth Instrum Comput* 1996;28:1–11.
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003;9:669–76.
- Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. *Cancer Res* 1995;55:4140–5.
- Greenberg DA, Jin K. VEGF and ALS: the luckiest growth factor? *Trends Mol Med* 2004;10:1–3.
- Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. *Eur J Neurosci* 2005;21:1304–14.
- Iga J, Ueno S, Yamauchi K, Motoki I, Tayoshi S, Ohta K, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. *Neurosci Lett* 2005;389:12–6.
- Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S, et al. Gene expression and association analysis of LIM (PDLIM5) in major depression. *Neurosci Lett* 2006;400:203–7.
- Irie H, Fujita M, Inokawa Y, Narita Y. Phase I clinical study of paroxetine HCl (Study 3): pharmacokinetics after single oral administration of paroxetine HCl 10, 20 and 40 mg to healthy adult male volunteers. *Pharmacol Ther* 2000;28:S47–68.
- Kim Y, Nam YJ, Lee C. Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. *Am J Med Genet B Neuropsychiatr Genet* 2006;141:332–5.
- Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. *Nat Genet* 2003;34:383–94.
- Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. *J Neurosci* 2003;23:10841–51.
- Nygren I, Larsson A, Johansson A, Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. *Neuroreport* 2002;13:2199–201.
- Ogawa H, Suefuji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. *Cardiology* 2000;93:93–9.
- Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. *J Comp Neurol* 2000;425:479–94.
- Rocc P, De Leo C, Eva C, Marchiaro L, Milani AM, Musso R, et al. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:1155–60.
- Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. *Biol Psychiatry* 2003;54:227–40.
- Scheufler KM, Dreves J, van Velthoven V, Reusch P, Klisch J, Augustin HG, et al. Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man. *J Cereb Blood Flow Metab* 2003;23:99–110.
- Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. *Cardiology* 2000;93:168–74.
- Solerte SB, Ferrari E, Cuzzoni G, Locatelli E, Giustina A, Zamboni M, et al. Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. *Dement Geriatr Cogn Disord* 2005;19:1–10.
- Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. *J Clin Invest* 2003;111:1843–51.
- Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. *Neurobiol Aging* 2002;23:237–43.
- Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. *Heart* 2005;91:465–71.
- Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Arch Gen Psychiatry* 2005;62:792–8.
- Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J Biol Chem* 1991;266:11947–54.
- Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. *Br J Ophthalmol* 1996;80:363–6.

## Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia

Shusuke Numata<sup>a</sup>, Shu-ichi Ueno<sup>a,b,\*</sup>, Jun-ichi Iga<sup>a</sup>, Ken Yamauchi<sup>a</sup>, Song Hongwei<sup>a</sup>, Ryota Hashimoto<sup>c,d,e</sup>, Masatoshi Takeda<sup>c,d</sup>, Hiroshi Kunugi<sup>e</sup>, Mitsuo Itakura<sup>f</sup>, Tetsuro Ohmori<sup>a</sup>

<sup>a</sup> Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-8-15 Kuramoto-cho, Tokushima 770-8503, Japan

<sup>b</sup> Department of Community and Psychiatric Nursing, School of Health Sciences, The University of Tokushima Graduate School, Japan

<sup>c</sup> The Osaka-Hamamatsu Joint Research Center For Child Mental Development, Osaka University Graduate school of Medicine, Japan

<sup>d</sup> Department of Psychiatry, Osaka University Graduate school of Medicine, Japan

<sup>e</sup> Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

<sup>f</sup> Division of Genetic Information, Institute for Genome Research, The University of Tokushima Graduate School, Japan

Received 11 October 2006; received in revised form 27 December 2006; accepted 2 January 2007

### Abstract

PDLIM5 modulates neuronal calcium signaling, co-localizes with synaptic vesicles of neurotransmitters and positive association between its gene and schizophrenia was reported but its relation is still ambiguous. The differential expression of the PDLIM5 gene both in the brain and in the lymphoblasts has been found in schizophrenia compared to control subjects. In this study, we measured the expression level of the PDLIM5 gene transcripts in the peripheral leukocytes from 19 medication-free and 21 chronically medicated schizophrenic patients as well as age- and sex-matched control subjects using a quantitative real-time PCR method. The mRNA levels of the PDLIM5 gene in the leukocytes of medication-free schizophrenic patients were significantly higher than those of control subjects. On the other hand, our group has previously shown that its mRNA expression in the leukocytes of medication-free major depressive patients was significantly lower compared with controls. There was no difference in the PDLIM5 mRNA levels between chronic schizophrenic patients with antipsychotic medication and their controls. Further, we failed to find any genetic association between the PDLIM5 gene and schizophrenia with six single nucleotide polymorphisms (SNPs) of the PDLIM5 gene in Japanese subjects (279 subjects each) and there was no significant relation between PDLIM5 gene and schizophrenia with the haplotype analysis ( $P = 0.48$ ), either. We suggest that the higher expression levels of the PDLIM5 mRNA in the peripheral leukocytes may be a candidate marker for medication-free schizophrenic patients.

© 2007 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** PDLIM5; Gene expression; Leukocytes; Association analysis; Schizophrenia

PDLIM5 is an intermediate protein that has been shown to regulate intracellular calcium levels by linking calcium channel and protein kinase C (PKC) [2,3,16]. PDLIM5 is ubiquitously expressed and its cellular localization in the brain is identical to Synapsin which is known to be involved in the neurotransmitter release [16]. The PDLIM5 gene lies on chromosome 4q22, a locus previously reported to be linked with schizophrenia [13,19]. While Kato et al. failed to find any association between the PDLIM5 gene and schizophrenia [15], Horiuchi

et al. found a significant association between them [6]. It was reported that the expression level of PDLIM5 mRNA was significantly increased in the postmortem brain tissues of patients with schizophrenia, bipolar disorder and major depression, but was decreased in the immortalized lymphoblastoid cell lines derived from patients with schizophrenia and bipolar disorder [10,11]. Our group has recently shown that levels of mRNA expression in the peripheral leukocytes of the PDLIM5 gene were significantly lower in medication-free major depressive patients compared with controls [8].

The expressional alterations of genes in the peripheral blood lymphocytes and leukocytes have been reported to indicate the changes of the central nervous systems in schizophrenia and

\* Corresponding author. Tel.: +81 886 33 7130; fax: +81 886 33 7131.  
E-mail address: [s-ueno@clin.med.tokushima-u.ac.jp](mailto:s-ueno@clin.med.tokushima-u.ac.jp) (S.-i. Ueno).

Table 1a  
Demographic data for medication-free schizophrenic patients studied in PDLIM5 mRNA expression analysis (N=19)

	Age (y.o)	Gender	Age at onset (years)	BPRS score	Family history of schizophrenia in first-degree relative
S1	25	M	22	64	+
S2	24	M	24	42	–
S3	24	M	24	31	–
S4	27	M	24	37	–
S5	36	M	36	34	–
S6	39	M	38	59	–
S7	27	M	26	58	–
S8	20	F	19	46	–
S9	23	F	23	48	–
S10	34	F	31	36	–
S11	47	F	47	30	–
S12	15	F	13	30	+
S13	26	F	21	100	–
S14	23	M	23	31	–
S15	28	M	25	63	–
S16	47	F	47	37	–
S17	37	F	21	36	–
S18	30	F	25	41	–
S19	45	F	43	36	+

The age (years old; y.o) represents the age of the subject when the leukocytes were drawn. M: male, F: female, '+' indicates that at least one of the first-degree relatives has schizophrenia.

major depressive disorder [7,8,9,17,21]. In this study, we measured the PDLIM5 mRNA expression levels in the peripheral leukocytes in unmedicated and medicated schizophrenic patients as well as in control subjects, using a quantitative real-time PCR method. In addition, we examined the genetic case-control study of the PDLIM5 gene with schizophrenia in Japanese subjects comprising of 279 patients with schizophrenia and 279 controls.

All patients and controls were biologically unrelated Japanese. The diagnosis of schizophrenia was made by at least two experienced psychiatrists according to DSM-IV criteria [1]. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale scores (BPRS) [20] when blood samples were taken. Age- and sex-matched controls were in good physical health without a history of any psychiatric or serious somatic diseases and taking any medication during the sample collection period. Proband who had first-degree relatives with psychiatric disorders were excluded from the control subjects.

For the measurement of expression levels of the PDLIM5 mRNA, the subjects consisted of 19 medication-free patients with schizophrenia (subject number S1–S19, Tables 1a and 1b)

(14 first-episode and drug-naïve schizophrenic patients, 5 schizophrenic patients without antipsychotic treatment for at least 2 months; 9 males and 10 females, mean age:  $30.4 \pm 9.3$ ), 19 age- and sex-matched controls (9 males and 10 females, mean age:  $30.6 \pm 8.6$ ), 21 chronically treated patients with schizophrenia who were stably controlled under the same amount dosage of antipsychotics for at least 3 months (subject number S20–S40, Tables 2a and 2b) (13 males and 8 females, mean age:  $47.7 \pm 11.3$ ) and 21 age- and sex-matched controls (mean age:  $47.7 \pm 11.1$ ).

For the genetic association study, we used DNA samples from 279 in patients (189 male and 90 female; mean age:  $51.3 \pm 13.7$  years) with schizophrenia from 13 psychiatric hospitals in the neighboring area of Tokushima Prefecture in Japan (population: about 820,000). Age- and sex-matched controls were selected from volunteers after assessing the psychiatric problems (189 male and 90 female; mean age:  $51.4 \pm 12.0$ ) for the association and haplotype-based case-control study.

All subjects signed written informed consent to participate in the expression and genetic association studies approved by the institutional ethics committees.

Table 1b  
PDLIM5 mRNA expression in medication-free schizophrenic (N=19) and control subjects (N=19)

	Male (N=9)	Female (N=10)	Total (N=19)
Schizophrenia (S1–S19)			
Age	$28.1 \pm 5.6$	$32.4 \pm 11.5$	$30.4 \pm 9.3$
The PDLIM5 mRNA expression before treatment	$1.13 \pm 0.3$	$1.29 \pm 0.3$	$1.21 \pm 0.3^*$
Control			
Age	$27.6 \pm 4.8$	$33.4 \pm 10.4$	$30.6 \pm 8.6$
The PDLIM5 mRNA expression	$0.95 \pm 0.2$	$1.03 \pm 0.4$	$1.00 \pm 0.3$

The mean PDLIM5 mRNA levels in the peripheral leukocytes from medication-free schizophrenia patients were significantly higher than those of age- and sex-matched controls (Mann–Whitney U test:  $P=0.023$ ); \* $P<0.05$ . No correlation between PDLIM5 mRNA levels and baseline BPRS scores were observed (Spearman's correlation coefficient:  $P=0.38$ ).

Table 2a  
Demographic data for chronic schizophrenic patients studied in PDLIM5 mRNA expression analysis ( $N=21$ )

	Age (y.o)	Gender	Medication	BPRS Score
S20	57	M	QTP 75 mg, LP 150 mg, CP 300 mg	55
S21	56	M	Ris 6 mg	29
S22	56	M	Ris 5 mg, QTP 200 mg, sulpiride 150 mg	44
S23	60	M	Ris 8 mg, LP 20 mg	67
S24	57	M	HPD 9 mg, BPD 9 mg propericyazine 60 mg	52
S25	40	M	Ris 12 mg	33
S26	46	M	Ris 6 mg, HPD 9 mg, sultopride 900 mg	49
S27	45	M	BPD 9 mg, clocapramine 75 mg	59
S28	31	M	BPD 2 mg, HPD 1 mg, LP 15 mg Perospirone 24 mg	49
S29	49	F	Ris 6 mg, HPD 6 mg, CP 20 mg, HPD decanoate 150 mg	33
S30	53	F	HPD 2.25 mg, sulpiride 150 mg	33
S31	65	F	HPD 4.5 mg, CP 37.5 mg	47
S32	51	F	Olz 10 mg	23
S33	43	F	Ris 6 mg, zotepine 50 mg	45
S34	54	F	Olz 20 mg, LP 50 mg	38
S35	54	M	Ris 12 mg, zotepine 150 mg timiperone 6 mg	42
Sc36	25	M	Ris 9 mg, perospirone 16 mg	39
Sc37	49	M	Ris 12 mg, LP 150 mg	54
Sc38	23	M	Ris 12 mg, LP 150 mg	38
Sc39	35	F	Olz 20 mg	33
Sc40	53	F	QTP 400 mg	27

The age (years old: y.o) represent the age of the subject when the leukocytes were drawn. M: male, F: female, Olz: olanzapine, Ris: risperidone, HPD: hapoperidol, BPD: bromperidol, LP; levom epromazine.

Total RNA was extracted from the peripheral leukocytes using the PAX gene Blood RNA kit (Qiagen, Tokyo, Japan) according to the manufacturer's recommendations. One microgram of total RNA was used for cDNA synthesis by QuantiTect Reverse Transcription Kit (Qiagen) after assessing RNA quality and quantity with NanoDrop (NanoDrop Technologies, DE, USA). Expression of the PDLIM5 gene transcript was quantified by real-time PCR with the TaqMan Gene Expression Assay (Applied Biosystems, CA, USA). Primers and probes (Hs00179051\_m1) were purchased from Applied Biosystems as well as Horiuchi's group [6]. GAPDH gene expression was used as an internal control and measurement of threshold cycle (Ct) was performed in triplicate. Data were collected and analyzed with Sequence Detector Software version 2.1 (Applied Biosystems) and the standard curve method. Relative gene expression was calculated as the ratio of PDLIM5 to GAPDH gene and the mean of the three replicate measures was assigned to each individual. Almost all of blood samples were taken in the morn-

ing before lunch. The expression of the PDLIM5 mRNA was not changed among blood samples collected at several points during the day time or over several weeks in the same control subjects.

Genotyping was performed using commercially available TaqMan probes (C\_2095059\_10, C\_16015055\_20, C\_3226622\_10, C\_16015313\_10, C\_1569781\_10, C\_11567561\_10) with Applied Biosystems 7500 Fast Real Time PCR System according to the protocol recommended by the manufacturer (Applied Biosystems). We selected six single nucleotide polymorphic (SNP) markers for genotyping according to linkage disequilibrium (LD) and haplotype blocks in the PDLIM5 gene region [6]. Two SNPs (rs10008257, rs2433320) in the 5'-flanking region and four SNPs left in the genomic region are covered about 169-kb in the whole 214-kb of the PDLIM5 gene. The heterozygocities of four of these six SNPs, rs10008257, rs2433320, rs2433327 and rs2452600 in Japanese population are reported as 0.39, 0.18, 0.26 and

Table 2b  
PDLIM5 mRNA expression in chronic treated schizophrenic ( $N=21$ ) and control subjects ( $N=21$ )

	Male ( $N=13$ )	Female ( $N=8$ )	Total ( $N=21$ )
Schizophrenia (S20–S40)			
Age	46.1 ± 12.7	50.4 ± 8.7	47.7 ± 11.3
The PDLIM5 mRNA expression	0.78 ± 0.2	0.93 ± 0.2	0.83 ± 0.2
Control			
Age	46.2 ± 12.3	50.1 ± 9.0	47.7 ± 11.1
The PDLIM5 mRNA expression	0.90 ± 0.3	1.14 ± 0.4	1.00 ± 0.3

The mean PDLIM5 mRNA levels in the peripheral leukocytes from schizophrenia patients who has been treated with antipsychotic drugs for many years were not different from controls' (Mann–Whitney  $U$  test:  $P=0.16$ ). No correlation between PDLIM5 mRNA levels and baseline BPRS scores were observed (Spearman's correlation coefficient:  $P=0.82$ ).




Fig. 1. Relative expression levels of PDLIM5 in the peripheral leukocytes in schizophrenic patients and control subjects. Compared with the normal control group, the mean PDLIM5 mRNA level in the leukocytes of medication-free schizophrenic patients ( $N=19$ ) was significantly higher (patients:  $1.21 \pm 0.29$ , controls:  $1.00 \pm 0.29$ , Mann–Whitney  $U$  test:  $P=0.023$ ). The mean PDLIM5 mRNA level in the leukocytes of chronic schizophrenic patients ( $N=21$ ) showed no significant difference compared with controls (patients:  $0.83 \pm 0.23$ , controls:  $1.00 \pm 0.32$ , Mann–Whitney  $U$  test:  $P=0.16$ ).

0.34, respectively. The heterozygosities of the other two SNPs, rs12641023 and rs14082, are not reported.

Statistical calculations were carried out using the SPSS Statistical Software Package 11.5 (SPSS, Tokyo, Japan). Expressional differences between patients and control subjects were calculated using the Mann–Whitney  $U$  test. Spearman correlation coefficients were used to evaluate the correlations between PDLIM5 mRNA levels and BPRS scores. Two-way ANOVA was performed to determine the independent and combined effects of age and the expression of PDLIM5 between groups. Allele and genotype frequencies of patients and control subjects were compared using Fisher's exact test. The SNPalyze 3.2 Pro software (DYNACOM, Japan) was used to estimate haplotype frequencies, LD, and permutation  $P$ -values. Pair-wise linkage disequilibrium indices,  $D'$  and  $r^2$ , were calculated in the control subjects. The criterion for significance was set at  $P < 0.05$  for all tests. Data are presented as mean  $\pm$  standard deviation.

Relative expression levels of PDLIM5 mRNA in 19 medication-free patients (S1–S19) were  $1.21 \pm 0.29$  in the range of 0.73–1.79, while  $1.00 \pm 0.29$  (range: 0.66–1.75) in healthy volunteers, showing a statistical difference (Mann–Whitney  $U$  test:  $P=0.023$ , Fig. 1). Mean BPRS scores were  $45.2 \pm 17.4$ . No correlation between PDLIM5 mRNA levels and baseline BPRS scores were observed (Spearman's correlation efficient:  $P=0.38$ ). There was no significant expressional difference of PDLIM5 mRNA levels either between males and females or between genotypes of the single nucleotide polymorphism (rs2433320) both in patients with schizophrenia and in control subjects.

Relative PDLIM5 mRNA level was  $0.83 \pm 0.23$  (0.46–1.18) in 21 chronically treated patients (S20–S40), while  $1.00 \pm 0.32$  (0.49–1.87) in healthy volunteers, showing no significant statistical difference (Mann–Whitney  $U$  test:  $P=0.16$ ; Fig. 1). Mean

chlorpromazine-equivalent doses were  $932.1 \pm 510.5$  mg/day and mean duration of treatment was  $23.5 \pm 10.7$  years and mean BPRS scores was  $43.1 \pm 10.8$ . No significant relationship between PDLIM5 mRNA levels and BPRS scores was observed (Spearman correlation efficient:  $P=0.71$ ). There was no significant expressional difference of PDLIM5 mRNA levels either between males and females or between genotypes of the single nucleotide polymorphism (rs2433320) both in patients with schizophrenia and in control subjects.

There were no significant deviations in all six SNPs from Hardy–Weinberg equilibrium in either patients or control subjects. Allele and genotype frequencies of the six SNPs are shown in Table 3. There were no associations between these SNPs and schizophrenia neither in the allelic frequency nor in the genotypic distributions. Although both rs2433320–rs2443327 and rs12641023–rs14082 were in a tight LD ( $D' = 0.936, 0.968$ , each), permutation test showed no significant difference in estimated frequencies of these haplotypes between the controls and patients (global permutation  $P=0.58, 0.45$ , each, Table 4). Haplotypes of six SNPs were evaluated, but no significant difference was observed in frequencies of any estimated haplotype or in distributions of all estimated haplotypes between the controls and patients (global permutation  $P=0.48$ ).

The present study is the first report on the PDLIM5 gene expression in the peripheral leukocytes in schizophrenia. The mean PDLIM5 mRNA levels in the peripheral leukocytes from medication-free schizophrenia patients were significantly higher than those of age- and sex-matched controls. Altered mRNA expression in the peripheral lymphocytes could reflect the altered metabolism of brain cells [4]. Our result is consistent with the result of higher expression in the postmortem brains from schizophrenic patient but not with the result of lower expression in the lymphoblastoid cells derived from schizophrenic patients [10,11]. The differences of the mRNA expression between studies may be partly attributed to the difference in the materials. When using lymphoblastoid cells, the effect of virus infection or chromosomal alterations during culture must be taken into account [12]. On the other hand, the mRNA expression level of PDLIM5 gene was not significantly higher in chronically treated schizophrenics compared with that of controls. This finding in the chronic patients may be a consequence of pharmacological effects of antipsychotics or clinical improvement. This result suggests that expression of PDLIM5 mRNA may not be trait-oriented but state-related change. To confirm whether the expression of this gene is a state marker, a follow-up investigation is needed in the same patients before and after treatment.

The pathophysiological mechanism remains unknown, but we speculate that the higher expression of PDLIM5 is related with putatively elevated  $Ca^{2+}$  signaling in schizophrenia. It has been suggested that abnormalities in  $Ca^{2+}$  signaling was associated with molecular etiology of schizophrenia. Regulator of G protein signaling-4 (RGS4) and B-cell lymphoma/leukaemia-2 gene (Bcl-2) which reduce free  $Ca^{2+}$  in a cell have been found to be down regulated in the temporal cortex of schizophrenic patients [14,18]. It was reported that there was high levels of free intracellular  $Ca^{2+}$  in platelets of schizophrenic patients

Table 3  
Genetic studies of PDLIM5 gene with schizophrenia in case-control samples

Group	Genotype			<i>n</i>	Hardy-Weinberg equilibrium	<i>P</i> -value	Allele		<i>P</i> -value
ra1 0008257	A/A	A/G	G/G				A	G	
sch	42	127	105	274	0.823	0.471	211	337	0.804
cont	34	140	102	276	0.229		208	344	
rs2433320									
sch	7	75	197	279	0.858	0.601	89	469	0.871
cont	11	70	198	279	0.205		92	466	
rs2433327	T/T	T/C	C/C				T	C	0.833
sch	169	88	16	273	0.414	0.917	426	120	
cont	164	92	15	271	0.788		420	122	
rs2452600	T/T	T/C	C/C				T	C	
sch	54	125	96	275	0.306	0.232	233	317	0.080
cont	68	130	81	279	0.325		266	292	
rs12641023	A/A	A/G	G/G				A	G	
sch	51	126	93	270	0.555	0.497	228	312	0.295
cont	42	131	103	276	0.924		215	337	
rs14082	A/A	A/G	G/G				A	G	
sch	58	124	91	273	0.243	0.302	240	306	0.141
cont	45	125	103	273	0.582		215	331	

sch: Schizophrenia, cont: control subjects. *P*-values are calculated by Fisher's exact test.

[22]. PDLIM5 regulates intracellular calcium levels by linking calcium channel and protein kinase C [2,3,16]. The levels of PDLIM5 might be up-regulated both in the brain and in the peripheral leukocytes in patients with schizophrenia in response to increased intracellular calcium levels. It has been demonstrated that antipsychotic drugs block IP3-induced release of Ca<sup>2+</sup> [23] and Ca<sup>2+</sup> dependence of PKC is well known [5]. So antipsychotic medication might normalize the up-regulation of PDLIM5 expression in schizophrenia by reducing Ca<sup>2+</sup> signaling.

PDLIM5 may be involved in other mental disorders. Iwamoto et al. reported that expression level of PDLIM5 was significantly and commonly increased in the postmortem brain tissues of patients with schizophrenia, major depression and bipolar disorder [11]. However, we have already shown that mean PDLIM5 mRNA level in the peripheral leukocytes of medication-free patients with major depression was significantly lower than in control subjects [8]. Therefore, the higher expression of this gene in the peripheral leukocytes of medication-free patients with schizophrenia may be disease-specific and not due to non-specific stress of psychiatric condition. Further investigations of other psychiatric diseases including bipolar disorder are needed.

Table 4  
Linkage disequilibrium (LD) indices (lower left are *r*<sup>2</sup>, upper right are *D'*)

	rs10008257	rs2433320	rs2443327	rs2452600	rs12641023	rs14082
rs10008257		0.37227	0.44147	0.26234	0.12734	0.15919
rs2433320	0.01632		0.9364	0.50709	0.37209	0.40838
rs2443327	0.03427	0.57719		0.54423	0.43945	0.45695
rs2452600	0.0447	0.05573	0.09941		0.19114	0.18689
rs12641023	0.00626	0.04284	0.05854	0.02152		0.95845
rs14082	0.01002	0.05068	0.09508	0.01918	0.93062	

Horiuchi et al. reported that there were significant association between polymorphisms (rs2433320 and rs2433322) of PDLIM5 gene and schizophrenia. Their group also showed that the different alleles of the rs2433320 showed different DNA-protein complexes on electrophoretic mobility shift assay and GA heterozygotic genotype might have higher transcriptional activity in schizophrenia [6]. However, our result showed that there was not significant association between schizophrenia and six polymorphisms of PDLIM5 gene, including rs2433320, and this result is consistent with a previous study with a large number of subjects (*n* = 562) [15]. In addition, neither patients nor controls showed a significant difference of the PDLIM5 mRNA expression in the peripheral leukocytes between GG and GA genotypes of this SNP in our subjects although the type II error was not denied.

In conclusion, our investigation revealed that the mean PDLIM5 mRNA levels in medication-free schizophrenic patients were significantly higher compared to those in controls and the chronic schizophrenic patients with antipsychotic treatment for many years showed almost the same expression levels as healthy control levels. There were no associations between schizophrenia and PDLIM5 gene. These results suggest that the higher expression levels of PDLIM5 mRNA in the leukocytes may be a candidate marker for medication-free schizophrenic patients. Further studies are necessary to confirm the present results.

#### Acknowledgements

The authors would like to thank all the volunteers who understood our study purpose and participated in this study and the physicians who helped us to take clinical data and blood samples in all the mental hospitals (Aizato Hospital,

Akita Hospital, Fujii Hospital, Hosogi Unity Hospital, Jounan Hospital, Jousei Hospital, Kawauchi Hospital, Nankai hospital, Sea Gull hospital, Taoka East Hospital, Tokushima University Hospital, Tokushima Prefectural Central Hospital and Yu-ai Hospital). The authors would like to thank Mrs. Akemi Okada and Mrs. Kumiko Kikuchi for their technical assistance. This work was supported by a Health and Labor Science Research Grant from the Japanese Ministry of Health, Labor and Welfare, a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology and a Grant-in-Aid for Scientific Research from the 21st Century COE program, Human Nutritional Science on Stress Control, Tokushima, Japan.

## References

- [1] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, fourth ed., American Psychiatric Press, Washington, DC, 1994.
- [2] I. Bach, The LIM domain: regulation by association, *Rev. Mech. Dev.* 91 (2000) 5–17.
- [3] Y. Chen, M. Lai, Y. Maeno-Hikichi, J. Zhang, Essential role of the LIM domain in the formation of the PKC epsilon-ENH-N-type  $Ca^{2+}$  channel complex, *Cell. Signal.* 18 (2006) 215–224.
- [4] A. Gladkevich, H.F. Kauffman, J. Korf, Lymphocytes as a neural probe: potential for studying psychiatric disorders, *Prog. Neuropsychopharmacol. Biol. Psychiatry* 28 (2004) 559–576.
- [5] B.D. Gomperts, P.E.R. Tatham, I.M. Kremer, *Signal Transduction*, Academic Press, San Diego, 2002.
- [6] Y. Horiuchi, M. Arai, K. Niizato, S. Iritani, E. Noguchi, T. Ohtsuki, M. Koga, T. Kato, M. Itokawa, T. Arinami, A polymorphism in the PDLIM5 gene associated with gene expression and schizophrenia, *Biol. Psychiatry* 59 (2006) 434–439.
- [7] J. Iga, S. Ueno, K. Yamauchi, I. Motoki, S. Tayoshi, K. Ohta, S. Hongwei, K. Morita, K. Rokutan, T. Ohmori, Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine, *Neurosci. Lett.* 389 (2005) 12–16.
- [8] J. Iga, S. Ueno, K. Yamauchi, S. Numata, I. Motoki, S. Tayoshi, S. Kinouchi, K. Ohta, S. Hongwei, K. Morita, K. Rokutan, H. Tanabe, A. Sano, T. Ohmori, Gene expression and association analysis of LIM (PDLIM5) in major depression, *Neurosci. Lett.* 400 (2006) 203–207.
- [9] T. Ilani, D. Ben-Shachar, R.D. Strous, M. Mazor, A. Sheinkman, M. Kotler, S. Fuchs, A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes, *Proc. Natl. Acad. Sci. U.S.A.* 98 (2001) 625–628.
- [10] K. Iwamoto, M. Bundo, S. Washizuka, C. Kakiuchi, T. Kato, Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia, *J. Hum. Genet.* 49 (2004) 227–231.
- [11] K. Iwamoto, C. Kakiuchi, M. Bundo, K. Ikeda, T. Kato, Molecular characterization of bipolar by comparing gene expression profiles of post-mortem brains of major mental disorders, *Mol. Psychiatry* 9 (2004) 406–416.
- [12] K. Iwamoto, T. Kato, Gene expression profiling in schizophrenia and related mental disorders, *Neuroscientist* 12 (2006) 349–361.
- [13] Japanese Schizophrenia Sib-Pair Linkage Group, Initial genome-wide scan for linkage with schizophrenia in the Japanese Schizophrenia Sib-Pair Linkage Group (JSSLG) families, *Am. J. Genet. B Neuropsychiatry Genet.* 120 (2003) 22–28.
- [14] L.F. Jarskog, J.H. Gilmore, E.S. Selinger, J.A. Lieberman, Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia, *Biol. Psychiatry* 48 (2000) 641–650.
- [15] T. Kato, Y. Iwayama, C. Kakiuchi, K. Iwamoto, K. Yamada, Y. Minabe, K. Nakamura, N. Mori, K. Fujii, S. Nanko, T. Yoshikawa, Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia, *Mol. Psychiatry* 10 (2005) 1045–1055.
- [16] Y. Maeno-Hikichi, S. Chang, K. Matsumura, M. Lai, H. Lin, N. Nakagawa, S. Kuroda, J.F. Zhang, A PKC epsilon-ENH-channel complex specifically modulates N-type  $Ca^{2+}$  channels, *Nat. Neurosci.* 6 (2003) 468–475.
- [17] C. Mehler-Wex, J.C. Duvigneau, R.T. Hartl, D. Ben-Shachar, A. Warnke, M. Gerlach, Increased mRNA levels of the mitochondrial complex 75-kDa subunit, A potential peripheral marker of early onset schizophrenia? *Eur. Child Adolesc. Psychiatry* 15 (2006) 504–507.
- [18] K. Mirmics, F.A. Middleton, G.D. Stanwood, D.A. Lewis, P. Levitt, Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia, *Mol. Psychiatry* 6 (2001) 293–301.
- [19] B.J. Mowry, K.R. Ewen, D.J. Nancarrow, D.P. Lennon, D.A. Nertney, H.L. Jones, M.S. O'Brien, C.E. Thornley, M.K. Walters, R.R. Crowe, J.M. Silverman, J. Endicott, L. Sharpe, N.K. Hayward, M.M. Gladis, S.J. Foote, D.F. Levinson, Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample, *Am. J. Med. Genet.* 96 (2000) 864–869.
- [20] J.F. Overall, D.R. Gorham, The Brief Psychiatric Rating Scale, *Psychol. Rep.* 10 (1962) 799–812.
- [21] O. Perl, T. Ilani, R.D. Strous, R. Lapidus, S. Fuchs, The  $\alpha$  nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes, *FASEB J.* 17 (2003) 1948–1950.
- [22] D. Ripova, A. Strunecka, V. Nemcova, I. Farska, Phospholipids and calcium alterations in platelets of schizophrenic patients, *Physiol. Res.* 46 (1997) 59–68.
- [23] S.R. Sczekan, F. Strumwasser, Antipsychotic drugs block IP3-dependent  $Ca^{2+}$ -release from rat brain microsome, *Biol. Psychiatry* 40 (1996) 497–502.

# Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling

Ryota Hashimoto<sup>1,2,3,\*†</sup>, Tadahiro Numakawa<sup>3,†</sup>, Takashi Ohnishi<sup>3,4,†</sup>, Emi Kumamaru<sup>3</sup>, Yuki Yagasaki<sup>3</sup>, Tetsuya Ishimoto<sup>5</sup>, Takeyuki Mori<sup>3,4</sup>, Kiyotaka Nemoto<sup>4</sup>, Naoki Adachi<sup>3</sup>, Aiko Izumi<sup>3</sup>, Sachie Chiba<sup>2,6</sup>, Hiroko Noguchi<sup>3</sup>, Tatsuyo Suzuki<sup>7</sup>, Nakao Iwata<sup>7</sup>, Norio Ozaki<sup>8</sup>, Takahisa Taguchi<sup>5</sup>, Atsushi Kamiya<sup>9</sup>, Asako Kosuga<sup>10</sup>, Masahiko Tatsumi<sup>10</sup>, Kunitoshi Kamijima<sup>10</sup>, Daniel R. Weinberger<sup>11</sup>, Akira Sawa<sup>12,13</sup> and Hiroshi Kunugi<sup>3</sup>

<sup>1</sup>The Osaka-Hamamatsu Joint Research Center For Child Mental Development and <sup>2</sup>Department of Psychiatry, Osaka University Graduate School of Medicine, D3, 2-2 Yamadaoka, 4-1-1 Suita, Osaka 565-0871, Japan, <sup>3</sup>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, <sup>4</sup>Department of Radiology, National Center Hospital of Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, <sup>5</sup>Neuronics R.G. Special Division for Human Life Technology, National Institute of Advanced Industrial Science and Technology, Ikeda, Osaka, Japan, <sup>6</sup>Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Koganei, Tokyo, Japan, <sup>7</sup>Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan, <sup>8</sup>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, <sup>9</sup>Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA, <sup>10</sup>Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan, <sup>11</sup>Genes, Cognition and Psychosis Program, Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA and <sup>12</sup>Department of Psychiatry and <sup>13</sup>Department of Neuroscience, Program in Cellular Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received May 22, 2006; Revised August 8, 2006; Accepted September 4, 2006

Disrupted-in-schizophrenia 1 (DISC1), identified in a pedigree with a familial psychosis with the chromosome translocation (1:11), is a putative susceptibility gene for psychoses such as schizophrenia and bipolar disorder. Although there are a number of patients with major depressive disorder (MDD) in the family members with the chromosome translocation, the possible association with MDD has not yet been studied. We therefore performed an association study of the DISC1 gene with MDD and schizophrenia. We found that Cys704 allele of the Ser704Cys single-nucleotide polymorphism (SNP) was associated with an increased risk of developing MDD ( $P = 0.005$ , odds ratio = 1.46) and stronger evidence for association in a multi-marker haplotype analysis containing this SNP ( $P = 0.002$ ). We also explored possible impact of Ser704Cys on brain morphology in healthy volunteers using MR imaging. We found a reduction in gray matter volume in cingulate cortex and a decreased fractional anisotropy in prefrontal white matter of individuals carrying the Cys704 allele compared with Ser/Ser704 subjects. In primary neuronal culture, knockdown of endogenous DISC1 protein by small interfering RNA resulted in the suppression of phosphorylation of ERK and Akt, whose signaling pathways are implicated in MDD. When effects of sDISC1 (Ser704) and cDISC1 (Cys704) proteins were examined separately, phosphorylation of ERK was greater in sDISC1 compared with cDISC1. A possible biological mechanism of MDD might be implicated by these convergent data that Cys704 DISC1 is associated with the lower biological activity on ERK signaling, reduced brain gray matter volume and an increased risk for MDD.

\*To whom correspondence should be addressed. Tel: +81 668793074; Fax: +81 668793059; Email: hashimor@psy.med.osaka-u.ac.jp

<sup>†</sup>The authors wish it to be known that, in their opinion, the first three authors should be regarded as joint First Authors.

## INTRODUCTION

The disrupted-in-schizophrenia 1 (DISC1) gene was initially identified at the breakpoint of a balanced translocation (1,11)(q42.1;q14.3), which segregated with major mental disorders in a large Scottish family (1). In this family, patients with schizophrenia, bipolar disorder and recurrent major depressive disorder (MDD) had been identified as carriers of the translocation (1,2). Subsequent genetic studies in several independent populations, including association and linkage studies, have also suggested that the DISC1 gene may be implicated in both schizophrenia and bipolar disorder (3–10). Previous studies suggest that genetic variations within the DISC1 gene, which increase risk for schizophrenia, are associated with the cerebral cortical gray matter and hippocampal volumes and function (9,11,12). However, no association study between the DISC1 gene and MDD has not yet been reported, despite there are more patients with MDD than those with schizophrenia in the original Scottish family members with translocation.

DISC1 is a multi-functional protein. Several research groups have identified DISC1 interacting proteins, which are associated with the components of the cytoskeleton and centrosome, such as dynein, Nudel, elongation protein zeta-1, etc. (13–18). DISC1 plays critical roles on the cerebral cortex development via microtubular dynamics and the DISC1–dynein complex (13). Another function of DISC1 may be modulation of cAMP signaling via an interaction with phosphodiesterase 4B, which also has been found to be disrupted by a balanced translocation in a patient with schizophrenia (19). Other functions of DISC1, including the mitochondrial and nuclear related functions, have also been suggested (15,20,21).

Here, we report an association of the genetic variations of DISC1, including Ser704Cys (rs821616) single-nucleotide polymorphism (SNP) and MDD. The risk allele (Cys704) for MDD is associated with the reduced gray matter volume and fractional anisotropy (FA) in prefrontal white matter in healthy subjects. Furthermore, the risk allele is linked to lower ERK activity (extracellular signal-regulated kinase), which has been suggested to have a role in the pathophysiology in MDD.

## RESULTS

### Association between the genetic variants of the DISC1 gene and major depression

We examined possible association between genetic variants in the DISC1 gene, including Ser704Cys SNP and MDD or schizophrenia. We genotyped 13 SNPs to cover the DISC1 locus at an average density of 31 kb. We found a significant association between genetic variations in DISC1 and MDD (Table 1). The Cys allele frequency of SNP12 (Ser704Cys) was greater in patients with MDD when compared with controls ( $\chi^2 = 7.88$ ,  $df = 1$ ,  $P = 0.005$ , odds ratio = 1.46, 95% CI 1.12–1.92). There was a weak evidence for an association with SNP1 ( $P = 0.048$ ). As previous association studies of the DISC1 gene applied three-marker haplotype analysis (4,8,9), we performed this analysis. Consistent with the

individual marker results, the three marker haplotypes containing SNPs 11–13 were associated with MDD: SNP11 (G allele)–SNP12(Cys)–SNP13(C allele) ( $P = 0.002$ ; Table 2). When we examined the association between genetic variations of DISC1 and schizophrenia, a weak evidence for association was observed with SNP7 ( $P = 0.0496$ ), whereas SNP12 (Ser704Cys) was not significantly associated with schizophrenia (Table 1). Because a prior study reported sex-dependent effects on association with schizophrenia (4), we examined males and females separately. This analysis revealed stronger evidence for association with SNP9 in female patients with schizophrenia ( $P = 0.0088$ ), but no association in male subjects, whereas a prominent gender effect was not found in MDD (Table 3). Three marker haplotypes were not associated with schizophrenia (data not shown). SNP12 showed a strong linkage disequilibrium (LD) with SNP10 and SNP11, moderate LD with SNP1 and SNP13 and weak LD with SNP6 in controls, and similar LD results were obtained in MDD and schizophrenia (Supplementary Material, Tables S1–S3). LD pattern of our data was similar to that of HapMap database in the Japanese population. Our results suggest that DISC1 is associated with MDD and with schizophrenia and that Ser704Cys SNP, in particular, is associated with MDD in our sample.

### Effects of the DISC1 Ser704Cys polymorphism on *in vivo* brain structure

As the abnormalities in the brain gray matter volume and white matter microstructure have been implicated in the biology of mood disorders and schizophrenia (22,23), we examined the possible effects of the Ser704Cys SNPs and other associated SNPs with schizophrenia on brain structure in healthy subjects (demographic information for Ser704Cys, Table 4). We found a bilateral (left dominant) reduction in the gray matter volume in the anterior cingulate cortex (ACC) [Brodmann area (BA) 24, Talairach coordinates  $x, y, z = -6, 27, 17$ , respectively,  $t = 3.58$ ], cingulate gyrus (BA24, Talairach coordinates  $x, y, z = 0, 3, 34$ , respectively,  $t = 3.7$ ) and the posterior cingulate gyrus (BA31, Talairach coordinates  $x, y, z = -9, -39, 36$ , respectively,  $t = 3.39$ ) in cys-DISC1 carriers (cys/cys and cys/ser) compared with ser/ser-DISC1 individuals by tensor-based morphometry (TBM) analysis (Fig. 1, upper panel). When we analyzed the effect of this SNP on brain morphology in the other direction (i.e. cys > ser), we found a significant reduction in the volumes of the lateral ventricle, interhemispheric fissure and the bilateral Sylvian fissure in ser/ser-DISC1 individuals compared with cys-DISC1 carriers (Fig. 1, lower panel). This finding suggests that cys-DISC1 carriers have expanded cerebrospinal fluid (CSF) space compared with ser/ser-DISC1 individuals, possibly consistent with our finding that cys carriers in our analysis have reductions in tissue volume measures. We did not detect significant differences in hippocampal volume related to this DISC1 polymorphism with even at a lenient threshold at  $P < 0.05$ . In comparison with ser/ser-DISC1 individuals, cys-DISC1 carriers demonstrated a significantly decreased FA value in the frontal white matter ( $P < 0.001$ ) (Fig. 2). The reversed contrast, i.e. increased FA in cys-DISC1 carriers, was not observed even at the level of

**Table 1.** Allele distributions for 13 SNPs in the DISC1 gene in patients with MDD, those with schizophrenia and controls

SNP	dbSNP	Distance from SNPI	Major/minor polymorphism	Amino acid substitution	Controls n = 717	MDD n = 373	P-value	OR	SZ n = 658	P-value	OR
1	rs6541281		C/T		0.122	0.094	<i>0.048</i>	<i>0.75</i>	0.105	0.16	—
2	rs3738401	17161	G/A	Gln264Arg	0.260	0.263	0.89	—	0.264	0.83	—
3	rs1340982	48898	C/T		0.461	0.456	0.82	—	0.459	0.92	—
4	rs1322784	115801	T/C		0.351	0.371	0.36	—	0.375	0.19	—
5	rs1535529	141475	C/T		0.425	0.441	0.48	—	0.410	0.42	—
6	rs7551537	159083	C/T		0.363	0.363	0.98	—	0.382	0.29	—
7	rs999710	197809	C/T		0.404	0.424	0.39	—	0.441	<i>0.05</i>	1.16
8	rs967433	218681	T/C		0.409	0.416	0.76	—	0.387	0.24	—
9	rs821577	253923	G/T		0.201	0.166	0.05	—	0.172	0.06	—
10	rs821597	289130	T/C		0.414	0.438	0.28	—	0.404	0.60	—
11	rs843979	317474	C/G		0.335	0.358	0.29	—	0.334	0.92	—
12	rs821616	331464	A/T	Ser704Cys	0.104	0.145	<i>0.005</i>	<i>1.46</i>	0.122	0.14	—
13	rs2806465	353160	G/C		0.376	0.378	0.92	—	0.370	0.75	—

Minor allele frequencies in controls are shown. SZ, schizophrenia, OR, odds ratio. Significant results ( $P < 0.05$ ) indicated by italics.

**Table 2.** Three-marker haplotype analysis among patients with major depression and controls

SNP	Haplotype											
1	2											
2	1	1										
3	1	1	2									
4		2	1	1								
5			2	1	1							
6				2	2	2						
7					1	1	1					
8						2	2	1				
9							2	2	2			
10								1	2	2		
11									1	2	2	2
12										2	2	2
13											2	2
Global P-value	<i>0.030</i>	0.19	<i>0.043</i>	0.81	0.74	0.55	0.69	0.20	<i>0.012</i>	0.17	0.057	
Individual P-value	<i>0.017</i>	<i>0.026</i>	<i>0.018</i>	0.24	0.25	0.25	0.19	<i>0.023</i>	<i>0.019</i>	<i>0.017</i>	<i>0.002</i>	
Haplotype frequency in control	0.050	0.201	0.180	0.123	0.136	0.108	0.081	0.064	0.018	0.096	0.074	
Haplotype frequency in MDD	0.026	0.250	0.233	0.104	0.116	0.089	0.060	0.035	0.000	0.130	0.116	

Major allele = 1, minor allele = 2. Individual P-value indicates the best P-value among the haplotypes. Significant results ( $P < 0.05$ ) indicated by italics.

$P < 0.05$ . Our results suggest that the Ser704Cys SNP of the DISC1 gene might affect human gray matter volume and white matter microstructure, particularly in peri-cingulate area. On the other hand, genotype effects of other SNPs, i.e. SNP1, SNP7 and SNP9 on the brain morphology or white matter microstructure, were not detected.

**DISC1 and ERK signaling**

ERK signaling and Akt signaling have been implicated in MDD (24,25). Thus, we investigated the possible involvement of DISC1 on ERK and Akt signaling pathways. The endogenous DISC1 function in cortical cultures was examined using small interfering RNA (siRNA) for DISC1, and robust decrease (70%) of endogenous DISC1 protein was confirmed (Fig. 3Aa and d). We found decreased levels of phosphorylation of ERK1/2 (pERK1/2: an activated form of ERK) and

phosphorylation of Akt (pAkt: an activated form of Akt) after DISC1-siRNA transfection, suggesting that endogenous DISC1 protein is involved in ERK and Akt activations (Fig. 3Aa–c). In contrast, the levels of total ERK1/2, Akt and TUJ1 (class III  $\beta$ -tubulin, a neuronal marker) proteins were not altered (Fig. 3Aa, quantified data (mean  $\pm$  SD): ERK1:  $1.15 \pm 0.22$ ,  $0.95 \pm 0.27$ ; ERK2:  $1.01 \pm 0.17$ ,  $0.99 \pm 0.22$ ; Akt:  $1.05 \pm 0.06$ ,  $1.09 \pm 0.04$ ; TUJ1:  $1.03 \pm 0.07$ ,  $1.01 \pm 0.07$ ; relative to none; scramble, si-DISC1, respectively).

To examine the effect of Ser704Cys SNP on ERK and Akt signaling, we overexpressed each type of DISC1 protein (sDISC1: DISC1 protein with Ser704; cDISC1: DISC1 protein with Cys704) using a sindbis virus-mediated gene delivery system. Neuronal cultures infected with the control viral construct [green fluorescence protein (GFP) only] were doubly stained with GFP signal and immunostaining signal

**Table 3.** Gender difference of allele distributions for 13 SNPs in the DISC1 gene among patients with schizophrenia, those with major depression and controls

SNP	SNP female				Male									
	Control	SZ	P-value	OR	MDD	P-value	OR	Control	SZ	P-value	OR	MDD	P-value	OR
	n = 366	n = 318			n = 226			n = 351	n = 340			n = 147		
1	0.135	0.102	0.061	—	0.091	<i>0.021</i>	<i>0.64</i>	0.108	0.107	0.96	—	0.099	0.65	—
2	0.258	0.274	0.52	—	0.279	0.44	—	0.262	0.254	0.74	—	0.238	0.43	—
3	0.466	0.459	0.80	—	0.465	0.97	—	0.456	0.459	0.91	—	0.442	0.69	—
4	0.344	0.385	0.12	—	0.356	0.68	—	0.359	0.366	0.78	—	0.395	0.29	—
5	0.414	0.399	0.58	—	0.469	0.063	—	0.437	0.421	0.53	—	0.398	0.25	—
6	0.373	0.381	0.77	—	0.354	0.51	—	0.352	0.384	0.22	—	0.378	0.44	—
7	0.404	0.447	0.12	—	0.427	0.44	—	0.405	0.437	0.23	—	0.418	0.69	—
8	0.411	0.390	0.42	—	0.425	0.65	—	0.406	0.384	0.40	—	0.401	0.89	—
9	0.209	0.154	<i>0.0088</i>	<i>1.45</i>	0.164	0.054	—	0.192	0.190	0.90	—	0.170	0.41	—
10	0.399	0.426	0.31	—	0.442	0.14	—	0.430	0.384	0.08	—	0.432	0.96	—
11	0.328	0.343	0.56	—	0.369	0.14	—	0.343	0.325	0.47	—	0.340	0.92	—
12	0.111	0.137	0.14	—	0.146	0.073	—	0.097	0.107	0.52	—	0.143	<i>0.035</i>	<i>0.64</i>
13	0.383	0.363	0.46	—	0.363	0.50	—	0.369	0.376	0.77	—	0.401	0.34	—

Minor allele frequencies in controls are shown. SZ, schizophrenia; OR, odds ratio. Significant results ( $P < 0.05$ ) indicated by italics.

**Table 4.** Demographic information for the brain MRI study


Variables	ser/ser-DISC1 (n = 86)	cys-DISC1 carriers (n = 22)	P-value
Age	35.1 (11.5)	40.1 (13.8)	0.08
Gender (M/F)	33/53	7/15	0.81
Education years	16.7 (2.8)	16.8 (3.4)	0.89
Full-scale IQ	111.8 (11.5)	109.2 (13.7)	0.39

Cys-DISC1 carriers (n = 22): cys/ser-DISC1 (n = 21) and cys/cys-DISC1 (n = 1). Mean values (SD) are presented.


by anti-microtubule-associated protein 2 (MAP2: a neuronal dendritic marker) antibody, as well as viral constructs of two types of DISC1 (sDISC1 and cDISC1) (Fig. 3Ba). About 85% of MAP2-positive cells in control-, sDISC1- or cDISC1-infected cortical cultures were GFP positive, indicating that the majority of neurons were infected, respectively [control (mean  $\pm$  SD):  $84.4 \pm 6.4\%$ ; sDISC1:  $86.6 \pm 5.1\%$ ; cDISC1:  $86.3 \pm 9.8\%$ , n=6 fields, selected randomly]. When cortical cultures infected by sDISC1 or cDISC1 were doubly stained with GFP signal and immunostaining signal by the DISC1 antibody, the sDISC1 and cDISC1 proteins were located in both cell body and neurites in punctuate manner, especially perinuclear region and neurite branch (Fig. 3Bb). As expression levels of GFP and TUJ1 were not altered by viral infections and both sDISC1- and cDISC1-infected cultures showed similar levels of DISC1 expression (Fig. 3Ca, quantified data (mean  $\pm$  SD): GFP:  $1.00 \pm 0.10$ ,  $0.92 \pm 0.15$ ; TUJ1:  $0.98 \pm 0.07$ ,  $0.98 \pm 0.09$ ; DISC1:  $5.43 \pm 0.52$ ,  $5.43 \pm 0.33$ , relative to control, sDISC1, cDISC1, respectively), we examined the phosphorylation of ERK and Akt in this system. Two-way ANOVA indicated significant main effects of viral infection ( $F = 202$ ,  $df = 2$ ,  $P < 0.001$ ) and measurement of protein levels ( $F = 161$ ,  $df = 8$ ,  $P < 0.001$ ) and interaction of these two factors ( $F = 44.4$ ,  $df = 16$ ,  $P < 0.001$ ). There were significant effects of viral infection in the measurements of pERK1/2 and

pAkt; however, neither total ERK1/2 nor Akt was altered after virus infection (pERK1:  $F = 104$ ,  $P < 0.001$ ; pERK2:  $F = 29.2$ ,  $P < 0.001$ ; pAkt:  $F = 9.0$ ,  $P < 0.01$ ; ERK1:  $F = 1.8$ ,  $P > 0.2$ ; ERK2:  $F = 3.0$ ,  $P > 0.1$ ; Akt:  $F = 0.2$ ,  $P > 0.8$ ) (Fig. 3C). *Post hoc* comparison revealed significant increases in pERK1/2 in sDISC1- or cDISC1-infected cultures compared with control (pERK1: sDISC1  $P < 0.01$ ; cDISC1  $P < 0.01$ ; pERK2: sDISC1  $P < 0.05$ ; cDISC1  $P < 0.05$ ) (Fig. 3Ca and b). The levels of ERK1 activation in sDISC1-overexpressing cultures were more intensive than those in cDISC1-overexpressing cultures ( $P < 0.01$ ) (Fig. 3Ca and b). A significant elevation of pAkt was observed in the sDISC1-overexpressing cultures compared with control ( $P < 0.05$ ), although an increase in the pAkt level by cDISC1 overexpression was not significant ( $P > 0.1$ ) (Fig. 3Ca and c). However, there were no significant difference of pAkt levels between sDISC1 and cDISC1 ( $P > 0.1$ ).

We next examined rescue experiments, transfection with sDISC1 or cDISC1 into primary culture knocked down to DISC1. In this experiment, siRNA for DISC1 decreased phosphorylation of ERK by  $\sim 50\%$  and there were significant effects of viral infection in the measurements of pERK1/2 (pERK1:  $F = 7.3$ ,  $P < 0.01$ ; pERK2:  $F = 9.4$ ,  $P < 0.01$ ) (Fig. 3D). *Post hoc* comparison revealed a significant elevation of pERK1 levels in the sDISC1-overexpressing cultures compared with si-DISC1 treatment ( $P < 0.01$ ), although an increase in the pERK1 level by cDISC1 overexpression was not statistically significant ( $P > 0.1$ ) (Fig. 3D). A significant elevation of pERK2 was observed in sDISC1- and cDISC1-infected cultures compared with si-DISC1 treatment (sDISC1:  $P < 0.05$ ; cDISC1:  $P < 0.05$ ) (Fig. 3D). Western blots showed that total ERK, Akt and TUJ1 protein levels were not changed and that pAkt levels were also rescued by DISC1 overexpression (Fig. 3Da). These results suggest the recovery of the activation of ERK1/2 and Akt after sDISC1- and cDISC1-overexpression in DISC1 knockdown cultures. The effect of rescue on phosphorylation of ERK was larger in sDISC1 compared with cDISC1, although the difference did not reach the statistical significance (Fig. 3D). This



**Figure 1.** Impact on the brain morphology of the Ser704Cys SNP in healthy subjects. (Upper panel) The SPM  $\{t\}$  is displayed onto T1-weighted MR images. Cys-DISC1 carriers ( $n = 22$ ) had reduced volumes in the bilateral ACC, cingulate gyrus and the posterior cingulate gyrus compared with ser/ser-DISC1 individuals ( $n = 86$ ). (Lower panel) The SPM $\{t\}$  is displayed on a standard maximum intensity projection images and T1-weighted MR images. Ser/Ser-DISC1 individuals demonstrated decreased volumes of the lateral ventricle, interhemispheric fissure and bilateral Sylvian fissure, indicating an expansion of the CSF space in cys-DISC1 carriers.




**Figure 2.** Disruption of white matter integrity revealed by DTI. The SPM $\{t\}$  is displayed onto a FA map. A significant reduction in FA in the prefrontal white matter was found in the cys-DISC1 carriers ( $n = 22$ ) when compared with individuals with ser/ser-DISC1 ( $n = 86$ ).

might be due to the complexity of this experiment (siRNA plus overexpression) compared with the overexpression only experiments, as the standard deviations of these experiments were larger than those of overexpression experiments. Our results suggest a possible role of DISC1 in the ERK and Akt signaling and an impact of Ser704Cys on ERK activation.

## DISCUSSION

Here, we report the evidence for association between MDD and the Ser704Cys SNP as well as several haplotypes including the Ser704Cys SNP. We also replicated earlier evidence for a weak association with schizophrenia which is stronger in female patients (4). Previous association studies with

schizophrenia suggested several regions in the DISC1 gene, such as intron2–intron3, intron4–intron9 and intron9–exon13 (4, 5, 8, 9). The region of intron8–intron9 is common across the studies. Consistent with the previous studies, two SNPs in intron9 were associated with schizophrenia in our study. Both false-positive and false-negative associations due to population stratification cannot be excluded in our case–control study, despite the precaution of ethnic matching of this study. Differences in gender ratio and ages between groups could be potential confounding factors. Therefore, it is necessary to carry out further investigations to confirm our findings in other samples. It has also suggested that allelic heterogeneity exists for association between the DISC1 gene and psychiatric illness (26), and this may explain different alleles being associated with illness in our sample compared with others.



**Figure 3.** Effects of the DISC1 protein on the ERK and Akt signaling in cortical neurons. (A) Suppression of phosphorylation of ERK and Akt in DISC1-siRNA-transfected cultures. Cortical cultures after DIV4 were treated with siRNA for DISC1 (si-DISC1; 100 nM) or control (scramble; 100 nM) for 72 h. Cortical cultures were harvested at DIV7 for western blotting for pERK1/2, ERK1/2, pAkt, Akt, DISC1 or TUJ1. The immunoblots shown are representative of four independent experiments (a). Quantification of the immunoreactivity of pERK1/2 (b), pAkt (c) or DISC1 (d). Quantitative data represent the mean  $\pm$  SD ( $n = 4$ ). \*\*\* $P < 0.001$  versus scramble. (B) (a) Double staining with GFP (green) signal and immunostaining signal by anti-MAP2 (red, a neuronal marker) antibody after sindbis virus-mediated gene transfer. Representative control (GFP only)-infected cortical cultures were shown. (b) GFP and DISC1 signal after sDISC1 (upper) or cDISC1 (lower) gene transfer, respectively. DISC1 localization was detected as a red signal. Virus infection was performed at DIV4 and infected cultures were fixed at DIV6 for immunostaining. Bar = 50  $\mu$ m. (C) Differential activation of ERK and Akt between sDISC1 and cDISC1. Samples for blotting pERK1/2, ERK1/2, pAkt, Akt, GFP, DISC1 or TUJ1 were prepared 24 h (DIV5) after viral infection at DIV 4 (a). The quantification of pERK1/2 (b) or pAkt (c) levels after overexpression of sDISC1 or cDISC1 was shown. The immunoblots shown are representative of four independent experiments. Quantitative data represent the mean  $\pm$  SD ( $n = 4$ ). \*\* $P < 0.01$ , \* $P < 0.05$  versus control, ## $P < 0.001$  versus sDISC1. (D) (a) Recovery of the activation of ERK1/2 and Akt after sDISC1 and cDISC1 overexpressing in DISC1 knockdown cultures. To downregulate endogenous DISC1, si-DISC1 was applied at DIV4 or DIV5 cultures. Sindbis virus-infection for sDISC1 or cDISC1 overexpression was performed 48 h after the si-DISC1 treatment. Samples for blotting for pERK1/2, ERK1/2, pAkt, Akt, GFP, DISC1 or TUJ1 were prepared 48 h after viral infection. The immunoblot images are representative of five independent experiments. (b) The quantification of pERK1/2 for each experimental condition was shown. Quantitative data represent the mean  $\pm$  SD ( $n = 5$ ). \*\* $P < 0.01$ , \* $P < 0.05$  versus si-DISC1.

We demonstrated that healthy subjects with the risk allele carriers for MDD (cys-DISC1) had relatively reduced the gray matter volumes in cingulate cortex, relatively expanded CSF space and reduced the FA values in the prefrontal white matter. This pattern of changes on magnetic resonance imaging (MRI) scanning, specifically the gray matter volume deficits in the ACC, expanded the CSF and reduced the FA values in prefrontal cortex, has been repeatedly reported in the studies of patients with schizophrenia and MDD (22,27–29). Several studies demonstrated a decreased volume in the ACC in patients with MDD in remission, MDD with a family history or in early onset depression (30–33) and abnormalities of cortical neuronal organization in postmortem brain of MDD have been reported in the ACC (34). It has been reported that relatively higher FA is associated with remission of MDD, following treatment with drugs or electroconvulsive therapy; however, reduced prefrontal FA has not been reported consistently in MDD (29,35–37). These various findings suggest that decreased gray matter volume and FA in the frontal area might be associated with the increased risk for MDD. Previous studies found that the risk haplotype of the DISC1 gene affected cortical gray matter and that Ser704Cys SNP had an impact on the hippocampal structure and function (9,11); however, we did not observe either effects of SNPs associated with schizophrenia in our sample on cortical gray matter or effects of Ser704Cys SNP on hippocampal volume. Moreover, in our study of the effect of Ser/Cys genotype on brain imaging derived phenotypes and clinical association, it is the cys allele that is relatively deleterious, whereas in an earlier study, it was the ser allele (9). These inconsistencies may relate to sample differences, methodological differences, and also to possible genetic and allelic heterogeneity.

We found robust effects of DISC1 on ERK and Akt signaling and evidence that the cDISC1 (the risk allele for MDD) might exert a weaker effect on the ERK activation than sDISC1. The involvement of ERK in the therapeutic mechanisms of mood disorder has been proposed (38,39). It has been shown that ERK can phosphorylate PDE4 and alter its activity (40,41) and that PDE inhibitors might have antidepressant efficacy (24). Taken together, the regulation of ERK signaling by DISC1 may contribute, at least in part, to the mechanisms of the risk for MDD. Structural imaging studies have demonstrated reduced gray matter volumes and white matter abnormality in several brain areas of patients with mood disorders relative to healthy controls, and postmortem morphometric brain studies also demonstrated cellular atrophy and/or loss (24). As the ERK kinase signaling is implicated in cytoskeletal remodeling, neurite outgrowth and cell survival (24) and decreased expression of ERK was observed in the postmortem brain of depressive patients (42), impaired ERK signaling could be related to the structural abnormality in major depression.

In conclusion, we have found evidence for association between genetic variation of DISC1 and MDD, brain morphology and ERK signaling pathway. Our data suggest that Ser704Cys might be a functional variant that impacts on neural mechanisms implicated in the biology of major depression.

## MATERIALS AND METHODS

### Subjects

Subjects for the clinical association study were recruited at Fujita Health University School of Medicine, Showa University School of Medicine and National Center of Neurology and Psychiatry, Japan. They were 373 patients with MDD [147 males and 226 females with mean age of 54.0 years (SD 16.0); mean age of onset of 46.5 years (SD 15.3)], 658 patients with schizophrenia [340 males and 318 females with mean age of 43.6 years (SD 14.6); mean age of onset of 24.2 years (SD 8.6)] and 717 healthy comparison subjects [351 males and 366 females with mean age of 41.3 years (SD 16.9)]. All the subjects were Japanese. Consensus diagnosis was made for each patient by at least two psychiatrists, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV Criteria). Control subjects were healthy volunteers who had no current or past contact to psychiatric services.

One hundred and eight healthy Japanese (biologically unrelated) for MR experiments were recruited at the National Center of Neurology and Psychiatry and screened by a questionnaire on medical history and excluded if they had neurological, psychiatric or medical conditions that could potentially affect the central nervous system, such as substance abuse or dependence, atypical headache, head trauma with loss of consciousness, asymptomatic or symptomatic cerebral infarction detected by the T2-weighted MRI, hypertension, chronic lung disease, kidney disease, chronic hepatic disease, cancer or diabetes mellitus. Detail demographics of subjects in genotypes of SNP1, SNP7, SNP9 and SNP12 (Ser704Cys) were noted in Supplementary Material. After description of the study, written informed consent was obtained from every subject. The study protocol was approved by institutional Ethics Committees.

### Genetic analysis

Venous blood was drawn from subjects and genomic DNA was extracted from the whole blood according to the standard procedures. Thirteen SNPs were genotyped using the TaqMan 5'-exonuclease allelic discrimination assay as described previously (43,44). Primers and probes for detection of the SNPs are available upon request. Statistical analysis of association studies was performed using SNPalyse (DYNACOM, Yokohama, Japan). Allele distributions between patients and controls were analyzed by the  $\chi^2$  test for independence. The measure of LD, denoted as  $D'$  and  $r^2$ , was calculated from the haplotype frequency using the expectation-maximization algorithm. Case-control haplotype analysis was performed by the permutation method to obtain the empirical significance (45). The global  $P$ -values represent the overall significance using the  $\chi^2$  test when the observed versus expected frequencies of all the haplotypes are considered together. The individual haplotypes were tested for association by grouping all others together and applying the  $\chi^2$ -test with 1 df.  $P$ -values were calculated on the basis of 10 000 replications. All  $P$ -values reported are two tailed. Statistical significance was defined at  $P < 0.05$ .

### Neuroimaging analysis

Brain MR procedure is described in Supplementary Material. The basic principle of TBM is to analyze the local deformations of an image and to infer local differences in the brain structure. The method was described in detail previously (46) (Supplementary Material). Diffusion tensor imaging (DTI) analysis was performed using FA maps by a voxel-by-voxel analysis (Supplementary Material). The statistical parametric maps of Jacobian determinants and FA values were analyzed using statistical parametric mapping (SPM) 2, which implements a 'general linear model'. To test hypotheses about regional population effects, data were analyzed by a two-sample *t*-test without global normalization. We used  $P < 0.001$  without a correction for multiple comparisons to avoid type-II error to explore whole brain and then applied small-volume correction ( $P < 0.01$ ) to each cluster. Since there has been no a priori hypothesis for FA changes associated with DISC1 polymorphism, we applied conservative statistical threshold ( $P < 0.001$ ) for the analysis of FA values. The resulting sets of *t*-values constituted the statistical parametric maps {SPM (*t*)}.

### Molecular biology

Primary cultures were prepared from the cerebral cortex of postnatal 2-day-old rats (Wister ST; SLC, Shizuoka, Japan) as reported previously (47,48).

The siRNA transfection was performed as reported previously (49). We used 21 nt siRNA duplexes with two nucleotides of the rat DISC1 mRNA coding region (113–131, GACCAGGCTACATGAGAAG, NM\_175596). Sense (GAC CAGGCUACAUGAGAAGtt) and antisense (CUUCUCAU GUAGCCUGGUctc) strands were chemically synthesized by Ambion Ltd (Cambridge, UK). The siRNA (GCGCGC UUUGUAGGAUUCG) named ScrambleII from Dharmacon Research Inc. was used as a scramble control. The plasmid for viral construction of the DISC1 gene was derived from pSinRep5 (Invitrogen, USA) and had two subgenomic promoters followed by a multiple cloning site for an arbitrary gene insertion and an enhanced GFP open-reading frame, thus the virus can produce both arbitrary protein and enhanced GFP independently in the infected cell (50). The control virus produces GFP only, whereas DISC1 virus produces both DISC1 and GFP independently. Detail procedure for viral construction is in Supplementary Material.

Immunocytochemistry was performed, as described previously (51). We used anti-MAP2 (1:1000; Sigma) or anti-DISC1 (1:100) (17) antibodies as a primary antibody, respectively. Alexa Fluor (1:1000, Molecular Probes) was applied as a secondary antibody. Fluorescent images were observed by an inverted microscope (Axiovert 200, ZEISS) with a CCD (cool SNAPfx, ZEISS).

Immunoblotting was carried out as described previously (47). Primary antibodies for immunoblotting were used at the following dilutions: anti-Akt (1:1000, Cell Signaling), anti-phospho-Akt (1:1000, Cell Signaling), anti-ERK (1:1000, Cell Signaling), anti-phospho-ERK (1:1000, Cell Signaling), anti-TUJ1 (1:5000, Berkeley antibody company), anti-GFP (1:1000, Medical & Biological Laboratories) and

anti-DISC1 antibodies (1:1000) (17). To quantify the amount of proteins after immunoblotting, we measured the density of immunoblots with an image-analysis software (Science Lab 98 Image Gauge; Fuji Photo Film Co. Ltd, Tokyo, Japan). The level of protein expression was indicated as a ratio that was normalized to control the condition (none, sole GFP-infected, or scramble-transfection, respectively) in each experiment. Statistical analysis was performed with unpaired *t*-test or ANOVA, followed by the Tukey *post hoc* comparisons when applicable.

### SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG Online.

### ACKNOWLEDGEMENTS

The authors thank Tomoko Shizuno for technical assistance. This work was supported in part by Grants-in-Aid from the Japanese Ministry of Health, Labor and Welfare (H17-kokoro-007 and H16-kokoro-002), the Japanese Ministry of Education, Culture, Sports, Science and Technology, CREST (Core research for Evolutional Science and Technology) of JST (Japan Science and Technology Agency), Research on Health Sciences focusing on Drug Innovation of the Japan Health Sciences Foundation, the Uehara Memorial Foundation, Takeda Science Foundation and Japan Foundation for Neuroscience and Mental Health.

*Conflict of Interest statement.* The authors declare that they have no conflict of interests.

### REFERENCES

1. Millar, J.K., Wilson-Annan, J.C., Anderson, S., Christie, S., Taylor, M.S., Semple, C.A., Devon, R.S., Clair, D.M., Muir, W.J., Blackwood, D.H. *et al.* (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum. Mol. Genet.*, **9**, 1415–1423.
2. Blackwood, D.H., Fordyce, A., Walker, M.T., St Clair, D.M., Porteous, D.J. and Muir, W.J. (2001) Schizophrenia and affective disorders—co-segregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. *Am. J. Hum. Genet.*, **69**, 428–433.
3. Ekelund, J., Hovatta, I., Parker, A., Paunio, T., Varilo, T., Martin, R., Suhonen, J., Ellonen, P., Chan, G., Sinsheimer, J.S. *et al.* (2001) Chromosome 1 loci in Finnish schizophrenia families. *Hum. Mol. Genet.*, **10**, 1611–1617.
4. Hennah, W., Varilo, T., Kestila, M., Paunio, T., Arajarvi, R., Haukka, J., Parker, A., Martin, R., Levitzky, S., Partonen, T. *et al.* (2003) Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. *Hum. Mol. Genet.*, **12**, 3151–3159.
5. Hodgkinson, C.A., Goldman, D., Jaeger, J., Persaud, S., Kane, J.M., Lipsky, R.H. and Malhotra, A.K. (2004) Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. *Am. J. Hum. Genet.*, **75**, 862–872.
6. Ekelund, J., Hennah, W., Hiekkalinna, T., Parker, A., Meyer, J., Lonnqvist, J. and Partonen, L. (2004) Replication of 1q42 linkage in Finnish schizophrenia pedigrees. *Mol. Psychiatry*, **9**, 1037–1041.
7. Sachs, N.A., Sawa, A., Holmes, S.E., Ross, C.A., DeLisi, L.E. and Margolis, R.L. (2005) A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. *Mol. Psychiatry*, **10**, 758–764.
8. Thomson, P.A., Wray, N.R., Millar, J.K., Evans, K.L., Hellard, S.L., Condie, A., Muir, W.J., Blackwood, D.H. and Porteous, D.J. (2005)

- Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. *Mol. Psychiatry*, **10**, 657–668.
9. Callicott, J.H., Straub, R.E., Pezawas, L., Egan, M.F., Mattay, V.S., Hariri, A.R., Verchinski, B.A., Meyer-Lindenberg, A., Balkissoon, R., Kolachana, B. *et al.* (2005) Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. *Proc. Natl Acad. Sci. USA*, **102**, 8627–8632.
  10. Hamshe, M.L., Bennett, P., Williams, N., Segurado, R., Cardno, A., Norton, N., Lambert, D., Williams, H., Kirov, G., Corvin, A. *et al.* (2005) Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. *Arch. Gen. Psychiatry*, **62**, 1081–1088.
  11. Cannon, T.D., Hennah, W., van Erp, T.G., Thompson, P.M., Lonnqvist, J., Huttunen, M., Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A.W. *et al.* (2005) Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. *Arch. Gen. Psychiatry*, **62**, 1205–1213.
  12. Burdick, K.E., Hodgkinson, C.A., Szeszko, P.R., Lencz, T., Ekholm, J.M., Kane, J.M., Goldman, D. and Malhotra, A.K. (2005) DISC1 and neurocognitive function in schizophrenia. *Neuroreport*, **16**, 1399–1402.
  13. Kamiya, A., Kubo, K., Tomoda, T., Takaki, M., Youn, R., Ozeki, Y., Sawamura, N., Park, U., Kudo, C., Okawa, M. *et al.* (2005) A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. *Nat. Cell Biol.*, **7**, 1067–1078.
  14. Millar, J.K., Christie, S. and Porteous, D.J. (2003) Yeast two-hybrid screens implicate DISC1 in brain development and function. *Biochem. Biophys. Res. Commun.*, **311**, 1019–1025.
  15. Morris, J.A., Kandpal, G., Ma, L. and Austin, C.P. (2003) DISC1 (disrupted-in-schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIP13, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. *Hum. Mol. Genet.*, **12**, 1591–1608.
  16. Miyoshi, K., Honda, A., Baba, K., Taniguchi, M., Oono, K., Fujita, T., Kuroda, S., Katayama, T. and Tohyama, M. (2003) Disrupted-in-schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. *Mol. Psychiatry*, **8**, 685–694.
  17. Ozeki, Y., Tomoda, T., Kleiderlein, J., Kamiya, A., Bord, L., Fujii, K., Okawa, M., Yamada, N., Hatten, M.E., Snyder, S.H. *et al.* (2003) Disrupted-in-schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. *Proc. Natl Acad. Sci. USA*, **100**, 289–294.
  18. Miyoshi, K., Asanuma, M., Miyazaki, I., Diaz-Corrales, F.J., Katayama, T., Tohyama, M. and Ogawa, N. (2004) DISC1 localizes to the centrosome by binding to kendrin. *Biochem. Biophys. Res. Commun.*, **317**, 1195–1199.
  19. Millar, J.K., Pickard, B.S., Mackie, S., James, R., Christie, S., Buchanan, S.R., Malloy, M.P., Chubb, J.E., Huston, E., Baillie, G.S. *et al.* (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. *Science*, **310**, 1187–1191.
  20. Sawamura, N., Sawamura-Yamamoto, T., Ozeki, Y., Ross, C.A. and Sawa, A. (2005) A form of DISC1 enriched in nucleus: altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. *Proc. Natl Acad. Sci. USA*, **102**, 1187–1192.
  21. James, R., Adams, R.R., Christie, S., Buchanan, S.R., Porteous, D.J. and Millar, J.K. (2004) Disrupted in schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. *Mol. Cell Neurosci.*, **26**, 112–122.
  22. Shenton, M.E., Dickey, C.C., Frumin, M. and McCarley, R.W. (2001) A review of MRI findings in schizophrenia. *Schizophr. Res.*, **49**, 1–52.
  23. Drevets, W.C., Ongur, D. and Price, J.L. (1998) Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. *Mol. Psychiatry*, **3**, 220–226.
  24. Manji, H.K., Quiroz, J.A., Sporn, J., Payne, J.L., Denicoff, K., Gray, N.A., Zarate, C.A., Jr and Charney, D.S. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. *Biol. Psychiatry*, **53**, 707–742.
  25. Coyle, J.T. and Duman, R.S. (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. *Neuron*, **38**, 157–160.
  26. Harrison, P.J. and Weinberger, D.R. (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol. Psychiatry*, **10**, 40–68.
  27. Manji, H.K., Drevets, W.C. and Charney, D.S. (2001) The cellular neurobiology of depression. *Nat. Med.*, **7**, 541–547.
  28. Kubicki, M., Westin, C.F., McCarley, R.W. and Shenton, M.E. (2005) The application of DTI to investigate white matter abnormalities in schizophrenia. *Ann. N. Y. Acad. Sci.*, **1064**, 134–148.
  29. Taylor, W.D., MacFall, J.R., Payne, M.E., McQuoid, D.R., Provenzale, J.M., Steffens, D.C. and Krishnan, K.R. (2004) Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. *Am. J. Psychiatry*, **161**, 1293–1296.
  30. Drevets, W.C., Price, J.L., Simpson, J.R., Jr, Todd, R.D., Reich, T., Vannier, M. and Raichle, M.E. (1997) Subgenual prefrontal cortex abnormalities in mood disorders. *Nature*, **386**, 824–827.
  31. Botteron, K.N., Raichle, M.E., Drevets, W.C., Heath, A.C. and Todd, R.D. (2002) Volumetric reduction in left subgenual prefrontal cortex in early onset depression. *Biol. Psychiatry*, **51**, 342–344.
  32. Bremner, J.D., Vythilingam, M., Vermetten, E., Nazeer, A., Adil, J., Khan, S., Staib, L.H. and Charney, D.S. (2002) Reduced volume of orbitofrontal cortex in major depression. *Biol. Psychiatry*, **51**, 273–279.
  33. Ballmaier, M., Toga, A.W., Blanton, R.E., Sowell, E.R., Lavretsky, H., Peterson, J., Pham, D. and Kumar, A. (2004) Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. *Am. J. Psychiatry*, **161**, 99–108.
  34. Chana, G., Landau, S., Beasley, C., Everall, I.P. and Cotter, D. (2003) Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. *Biol. Psychiatry*, **53**, 1086–1098.
  35. Taylor, W.D., Payne, M.E., Krishnan, K.R., Wagner, H.R., Provenzale, J.M., Steffens, D.C. and MacFall, J.R. (2001) Evidence of white matter tract disruption in MRI hyperintensities. *Biol. Psychiatry*, **50**, 179–183.
  36. Alexopoulos, G.S., Kiosses, D.N., Choi, S.J., Murphy, C.F. and Lim, K.O. (2002) Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. *Am. J. Psychiatry*, **159**, 1929–1932.
  37. Nobuhara, K., Okugawa, G., Minami, T., Takase, K., Yoshida, T., Yagyu, T., Tajika, A., Sugimoto, T., Tamagaki, C., Ikeda, K. *et al.* (2004) Effects of electroconvulsive therapy on frontal white matter in late-life depression: a diffusion tensor imaging study. *Neuropsychobiology*, **50**, 48–53.
  38. Einat, H., Yuan, P., Gould, T.D., Li, J., Du, J., Zhang, L., Manji, H.K. and Chen, G. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. *J. Neurosci.*, **23**, 7311–7316.
  39. Shirayama, Y., Chen, A.C., Nakagawa, S., Russell, D.S. and Duman, R.S. (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. *J. Neurosci.*, **22**, 3251–3261.
  40. Baillie, G.S., MacKenzie, S.J., McPhee, I. and Houslay, M.D. (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. *Br. J. Pharmacol.*, **131**, 811–819.
  41. Hill, E.V., Houslay, M.D. and Baillie, G.S. (2005) Investigation of extracellular signal-regulated kinase 2 mitogen-activated protein kinase phosphorylation and regulation of activity of PDE4 cyclic adenosine monophosphate-specific phosphodiesterases. *Methods Mol. Biol.*, **307**, 225–237.
  42. Dwivedi, Y., Rizavi, H.S., Roberts, R.C., Conley, R.C., Tamminga, C.A. and Pandey, G.N. (2001) Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. *J. Neurochem.*, **77**, 916–928.
  43. Hashimoto, R., Okada, T., Kato, T., Kosuga, A., Tatsumi, M., Kamijima, K. and Kunugi, H. (2005) The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder. *Biol. Psychiatry*, **57**, 1097–1102.
  44. Hashimoto, R., Suzuki, T., Iwata, N., Yamanouchi, Y., Kitajima, T., Kosuga, A., Tatsumi, M., Ozaki, N., Kamijima, K. and Kunugi, H. (2005) Association study of the frizzled-3 (FZD3) gene with schizophrenia and mood disorders. *J. Neural. Transm.*, **112**, 303–307.
  45. Good, P. (2000) *Permutation Tests. A Practical Guide to Resampling Methods for Testing Hypothesis*, 2nd edn. Springer-Verlag, New York.
  46. Ohnishi, T., Hashimoto, R., Mori, T., Nemoto, K., Moriguchi, Y., Iida, H., Noguchi, H., Nakabayashi, T., Hori, H., Ohmori, M. *et al.* (2006) The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. *Brain*, **129**, 399–410.

47. Numakawa, T., Yokomaku, D., Kiyosue, K., Adachi, N., Matsumoto, T., Numakawa, Y., Taguchi, T., Hatanaka, H. and Yamada, M. (2002) Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons. *J. Biol. Chem.*, **277**, 28861–28869.
48. Numakawa, T., Yamagishi, S., Adachi, N., Matsumoto, T., Yokomaku, D., Yamada, M. and Hatanaka, H. (2002) Brain-derived neurotrophic factor-induced potentiation of Ca(2+) oscillations in developing cortical neurons. *J. Biol. Chem.*, **277**, 6520–6529.
49. Numakawa, T., Nakayama, H., Suzuki, S., Kubo, T., Nara, F., Numakawa, Y., Yokomaku, D., Araki, T., Ishimoto, T., Ogura, A. *et al.* (2003) Nerve growth factor-induced glutamate release is via p75 receptor, ceramide, and Ca(2+) from ryanodine receptor in developing cerebellar neurons. *J. Biol. Chem.*, **278**, 41259–41269.
50. Kawamura, M., Namba, H., Otsu, Y., Hayashi, Y., Takei, N. and Nawa, H. (2003) Characterization of novel bicistronic Sindbis virus vectors, SinEGdsp and SinIRES-EG, in cultured neurons. *Recent Res. Dev. Neurochem.*, **6**, 105–120.
51. Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K. *et al.* (2004) Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. *Hum. Mol. Genet.*, **13**, 2699–2708.

# The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia

Takashi Ohnishi,<sup>1,2,4</sup> Ryota Hashimoto,<sup>2</sup> Takeyuki Mori,<sup>1,2</sup> Kiyotaka Nemoto,<sup>1</sup> Yoshiya Moriguchi,<sup>1</sup> Hidehiro Iida,<sup>4</sup> Hiroko Noguchi,<sup>2</sup> Tetsuo Nakabayashi,<sup>2,3</sup> Hiroaki Hori,<sup>2,3</sup> Mayu Ohmori,<sup>3</sup> Ryoutarō Tsukue,<sup>3</sup> Kimitaka Anami,<sup>3</sup> Naotugu Hirabayashi,<sup>3</sup> Seiichi Harada,<sup>3</sup> Kunimasa Arima,<sup>3</sup> Osamu Saitoh<sup>3</sup> and Hiroshi Kunugi<sup>2</sup>

<sup>1</sup>Department of Radiology, National Center Hospital of Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, <sup>2</sup>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, <sup>3</sup>Department of Psychiatry, National Center Hospital of Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo and <sup>4</sup>Department of Investigative Radiology, Research Institute, National Cardiovascular Center, Osaka, Japan

Correspondence to: Takashi Ohnishi, Department of Radiology, National Center Hospital of Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry 4-1-1 Ogawa Higashi, Kodaira City, Tokyo, Japan 187-0031  
E-mail: tohnishi@hotmail.com

The catechol-O-methyl transferase (COMT) gene is considered to be a promising schizophrenia susceptibility gene. A common functional polymorphism (Val158Met) in the COMT gene affects dopamine regulation in the prefrontal cortex (PFC). Recent studies suggest that this polymorphism contributes to poor prefrontal functions, particularly working memory, in both normal individuals and patients with schizophrenia. However, possible morphological changes underlying such functional impairments remain to be clarified. The aim of this study was to examine whether the Val158Met polymorphism of the COMT gene has an impact on brain morphology in normal individuals and patients with schizophrenia. The Val158Met COMT genotype was obtained for 76 healthy controls and 47 schizophrenics. The diagnostic effects, the effects of COMT genotype and the genotype-diagnosis interaction on brain morphology were evaluated by using a voxel-by-voxel statistical analysis for high-resolution MRI, a tensor-based morphometry. Patients with schizophrenia demonstrated a significant reduction of volumes in the limbic and paralimbic systems, neocortical areas and the subcortical regions. Individuals homozygous for the Val-COMT allele demonstrated significant reduction of volumes in the left anterior cingulate cortex (ACC) and the right middle temporal gyrus (MTG) compared to Met-COMT carriers. Significant genotype-diagnosis interaction effects on brain morphology were noted in the left ACC, the left parahippocampal gyrus and the left amygdala-uncus. No significant genotype effects or genotype-diagnosis interaction effects on morphology in the dorsolateral PFC (DLPFC) were found. In the control group, no significant genotype effects on brain morphology were found. Schizophrenics homozygous for the Val-COMT showed a significant reduction of volumes in the bilateral ACC, left amygdala-uncus, right MTG and left thalamus compared to Met-COMT schizophrenics. Our findings suggest that the Val158Met polymorphism of the COMT gene might contribute to morphological abnormalities in schizophrenia.

**Keywords:** schizophrenia; polymorphism; COMT; ACC; DLPFC

**Abbreviations:** ACC = anterior cingulate cortex; COMT = catechol-*O*-methyl transferase; DLPFC = dorsolateral prefrontal cortex; FDR = false discovery rate; IQ = intelligence quotient; JART = Japanese version of National Adult Reading Test; ROI = region of interest; SPM = statistical parametric mapping; TBM = tensor-based morphometry

Received July 15, 2005. Revised September 21, 2005. Accepted October 27, 2005. Advance Access publication December 5, 2005

## Introduction

Schizophrenia is a severe neuropsychiatric disorder with deficits of multiple domains of cognitive functions, volition and emotion. Family and twin studies have provided cumulative evidence for a genetic basis of schizophrenia (Kendler, 1983; McGue *et al.*, 1983; Sullivan *et al.*, 2003); however, identification of the underlying susceptibility loci has been limited. Collective data have suggested that the aetiology of schizophrenia involves the interplay of complex polygenic influences and environmental risk factors operating on brain maturational processes (Harrison *et al.*, 2005).

*In vivo* neuroimaging studies have demonstrated that brain abnormalities should play an important role in the pathophysiology of schizophrenia. Structural MRI studies have demonstrated relatively consistent brain abnormalities in patients with schizophrenia, such as enlargement of the ventricular system and regional volume decrease in the temporal lobe structures (Gaser *et al.*, 2001; Okubo *et al.*, 2001; Shenton *et al.*, 2001; Davidson and Heinrichs, 2003). Studies with schizophrenics and their healthy siblings demonstrate that even healthy siblings share some of morphological abnormalities observed in schizophrenia (Steel *et al.*, 2002; Gogtay *et al.*, 2003). A recent morphological MR study revealed that a common polymorphism of the brain-derived neurotrophic factor, one of the well-known schizophrenia susceptibility genes, affected the anatomy of the hippocampus and prefrontal cortex (PFC) in healthy individuals (Pezawas *et al.*, 2004). Furthermore, some studies have suggested that environmental factors interact with genetic factors (Cannon *et al.*, 1993; Nelson *et al.*, 2004). For example, obstetric complications are well known non-genetic risk factors of schizophrenia. However, a previous study suggested that obstetric complications might induce brain morphological abnormalities in schizophrenics and their siblings, but not in comparison with subjects at low genetic risk for schizophrenia (Cannon *et al.*, 1993). These facts suggest that genetic factors should have considerable impact on brain morphology in patients with schizophrenia.

Catechol-*O*-methyl transferase (COMT) is a promising schizophrenia susceptibility gene because of its role in monoamine metabolism (Goldberg *et al.*, 2003; Stefanis *et al.*, 2004; Harrison *et al.*, 2005). A common single nucleotide polymorphism (SNP) of the COMT gene producing an amino acid substitution of methionine (met) to valine (val) at position 108/158 (Val158Met) affects dopamine regulation in the PFC (Palmatier *et al.*, 1999). This polymorphism impacts on the stability of the enzyme, such that the Val-COMT allele has significantly lower enzyme activity than the Met-COMT allele (Weinberger *et al.*, 2001; Chen *et al.*, 2004). Several

studies have revealed that the Val-COMT allele is associated with poorer performances, compared to the Met-COMT allele, in cognitive tasks of frontal function such as the Wisconsin Card Sorting Test (WCST) and N-back task (Egan *et al.*, 2001; Weinberger *et al.*, 2001; Goldberg *et al.*, 2003). The underlying mechanism of such behavioural differences may be related to lower prefrontal dopamine levels arising from higher dopamine catabolism mediated by the Val-COMT allele (Chen *et al.*, 2004; Tunbridge *et al.*, 2004).

The results of studies on the association between the Val158Met polymorphism and schizophrenia have, however, been controversial (Daniels *et al.*, 1996; Kunugi *et al.*, 1997; Ohmori *et al.*, 1998; Norton *et al.*, 2002; Galderisi *et al.*, 2005; Ho *et al.*, 2005). The result of a meta-analysis was even more inconclusive (Fan *et al.*, 2005). Such inconsistency was also found in associations between frontal functions and the Val158Met polymorphism (Egan *et al.*, 2001; Weinberger *et al.*, 2001; Goldberg *et al.*, 2003; Ho *et al.*, 2005). The possible morphological changes due to the COMT gene might be present and play a role in susceptibility to schizophrenia and in giving rise to impaired frontal functions. However, morphological changes underlying functional impairments remain to be clarified.

A recent advancement of methods for MR volumetry, such as voxel-based morphometry and deformation-based morphometry [or tensor-based morphometry (TBM)], allows us to explore and analyse brain structures of schizophrenics (Wright *et al.*, 1995; Gaser *et al.*, 2001). Using TBM techniques, we investigated the association between the Val158-Met polymorphism of the COMT gene and brain morphology in normal individuals and patients with schizophrenia. The aim of this study was to clarify whether there are significant genotype and/or genotype-disease interaction effects on brain morphology.

## Methods

### Subjects

Seventy-six healthy subjects and forty-seven patients with schizophrenia participated in the study. All the subjects were biologically unrelated Japanese. Written informed consent was obtained from all the subjects in accordance with ethical guidelines set by a local ethical committee. All normal subjects were screened using a questionnaire on medical history and excluded if they had neurological, psychiatric or medical conditions that could potentially affect the CNS, such as substance abuse or dependence, atypical headache, head trauma with loss of consciousness, asymptomatic or symptomatic cerebral infarctions detected by T<sub>2</sub>-weighted MRI, hypertension, chronic lung

disease, kidney disease, chronic hepatic disease, cancer, or diabetes mellitus. The patients were diagnosed on the basis of DSM-IV criteria, information from medical records and a clinical interview. All patients were stable and/or partially remitted at the time of MR measurement and neuropsychological tests.

According to genotypes, each group (control and schizophrenia) was categorized into three groups; the homozygous Val-COMT group (control:  $n = 38$ , two were left-handed, schizophrenia:  $n = 19$ , one was left-handed), the Val/Met-COMT group (control:  $n = 25$ , three were left-handed, schizophrenia:  $n = 22$ , all were right-handed) and the remaining homozygous Met-COMT group (control:  $n = 13$ , all were right-handed, schizophrenia:  $n = 6$ , all were right-handed). Because of the small number of subjects with homozygous Met-COMT, the Val/Met-COMT and homozygous Met-COMT groups were combined and treated as one group, the Met-COMT carriers. Table 1 shows the characteristics of each group. All groups were of comparable age, gender ( $\chi^2$  test,  $df = 3$ ,  $P = 0.38$ ) and handedness ( $\chi^2$ -test,  $df = 3$ ,  $P = 0.53$ ). No genotype effects and genotype-diagnosis interaction effects were found in years of education, scores of full scale Intelligence Quotient (IQ) and scores of premorbid IQ [Japanese version of National Adult Reading Test (JART) score], however, patients who had fewer years of education ( $P < 0.0001$ ), had lower scores of both full scale IQ and JART ( $P < 0.001$ ). The duration of illness, medication and hospitalization, the age at disease onset and drug dose (chlorpromazine equivalent) of those homozygous for the Val-COMT did not differ from the Met-COMT carriers.

### SNP genotyping

Venous blood was drawn from subjects and genomic DNA was extracted from whole blood according to the standard procedures. The Val158Met polymorphism of the COMT gene (dbSNP accession: rs4680) was genotyped using the TaqMan 5'-exonuclease allelic discrimination assay, described previously (Hashimoto *et al.*, 2004, 2005). Briefly, primers and probes for detection of the SNP are: forward primer 5'-GACTGTGCCGCCATCAC-3', reverse primer 5'-CAGGCATGCACACCTTGTC-3', probe 1 5'-VIC-TTTCGCTGCGGTGAAG-MGB-3' and probe 2 5'-FAM-CGCTGGCATGAAG-MGB-3'. PCR cycling conditions were: at 95°C for 10 min, 50 cycles of 92°C for 15 s and 60°C for 1 min.

### MRI procedures

All MR studies were performed on a 1.5 tesla Siemens Magnetom Vision plus system. A three dimensional (3D) volumetric acquisition of a T<sub>1</sub>-weighted gradient echo sequence produced a gapless series of thin sagittal sections using an MPRage sequence (TE/TR, 4.4/11.4 ms; flip angle, 15°; acquisition matrix, 256 × 256; 1 NEX, field of view, 31.5 cm; slice thickness, 1.23 mm).

### Image analysis (TBM)

The basic principle of TBM is to analyse the local deformations of an image and to infer local differences in brain structure. In TBM, MRI scans of individual subjects are mapped to a template image with three-dimensional (3D) non-linear normalization routines. Local deformations were estimated by a univariate Jacobian approach. The basic principle of TBM is the same as a method used in a previous report described as deformation-based morphometry (Gaser *et al.*, 2001). Firstly, inhomogeneities in MR images were corrected using a bias correction function in statistical parametric mapping (SPM2),

then the corrected image was scalp-edited by masking with a probability image of brain tissue obtained from each image using a segmentation function in SPM2. Using a linear normalization algorithm in SPM2, all brains were resized to a voxel size of 1.5 mm and adjusted for orientation and overall width, length and height (Fig. 1A). Therefore, brains were transformed to the anatomical space of a template brain whose space is based on Talairach space (Talairach and Tournoux, 1988). Subsequent non-linear normalization introduced local deformations to each brain to match it to the same scalp-edited template brain (Fig. 1C). The non-linear transformation was done using the high-dimension-warping algorithm (Ashburner and Friston, 2004). After the high dimensional warping, each image (Fig. 1B) looks similar to the template (Fig. 1C). Figure 2 demonstrated a mean MR image of 76 controls (left) and a mean MR image of 47 schizophrenics after high dimensional warping (Fig. 2). We obtained 3D deformation fields for every brain (Fig. 1D). Each of these 3D deformation fields consists of displacement vectors for every voxel, which describe the 3D displacement needed to locally deform the brain to match it to the template. We calculated the Jacobian determinants to obtain voxel by voxel parametric maps of local volume change relative to the template brain (Fig. 1E). The local Jacobian determinant is a parameter commonly used in continuum mechanics (Gurtin, 1987), which characterizes volume changes, such as local shrinkage or enlargement caused by warping. The parametric maps of Jacobian determinants were analysed using SPM2, which implements a 'general linear model'. To test hypotheses about regional population effects and interaction, data were analysed by an analysis of covariance (ANCOVA) without global normalization. There was no significant difference in age among the four groups, however, patients with schizophrenia, particularly those homozygous for the Val-COMT allele, were older than controls. Therefore, we treated age and years of education and scores of JART as nuisance variables. Since TBM explores the entire brain (grey matter, CSF space and white matter) at once, the search volume of TBM has a large number of voxels and since our interest was in morphological changes in the grey matter and CSF space, we excluded white matter tissue from analyses by using an explicit mask (Fig. 1F). We used  $P < 0.001$ , corrected for multiple comparisons with false discovery rate (FDR)  $< 0.05$  as a statistical threshold. The resulting sets of  $t$  values constituted the statistical parametric maps {SPM( $t$ )}. Firstly, we estimated the main effects, the genotype effect in total subjects (the Val/Val-COMT versus the Met-COMT carriers) and the diagnostic effect (schizophrenia versus controls) and then the genotype-diagnosis interaction effect was estimated. Furthermore, the effects of genotypes in each group (controls carrying the Val/Val-COMT gene versus controls carrying the Met-COMT gene and schizophrenics carrying the Val/Val-COMT gene versus schizophrenics carrying the Met-COMT gene) were estimated within the ANCOVA design matrix. Anatomical localization accorded both to MNI coordinates and Talairach coordinates obtained from M. Brett's transformations ([www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html](http://www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html)) and are presented as Talairach coordinates (Talairach and Tournoux, 1988). Since previous studies have demonstrated the association between the Val158Met polymorphism and the dorsolateral PFC (DLPFC), we applied an additional hypothesis-driven region of interest (ROI) method to test regional population effects in the DLPFC. For this ROI analysis, we used the Wake Forest University PickAtlas (Maldjian *et al.*, 2003) within the ANCOVA design matrix for SPM analysis. We set  $P < 0.05$  (uncorrected) with a small volume correction ( $P < 0.05$  within the ROI) to assess grey matter volume changes in the DLPFC (Brodmann area 46, 9 and 8).